In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. Invest New Drugs 2012;30(1):405-7.
. Inverse correlation between circulating levels of TNF-related apoptosis-inducing ligand and 17β-estradiol. J Clin Endocrinol Metab 2014;99(4):E659-64.
. Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opin Ther Targets 2011;15(8):931-42.
. Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival. Reproduction 2014;148(2):191-8.
. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 2011;17(4):762-70.
. Editorial: innovative therapeutic approaches for the treatment of pediatric autoimmune and inflammatory diseases. Curr Pharm Des 2012;18(35):5728.
. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011;17(9):2712-24.
. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012;97(11):1722-30.
. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes 2010;59(5):1261-5.
. Circulating TRAIL shows a significant post-partum decline associated to stressful conditions. PLoS One 2011;6(12):e27011.
.